Europos Sąjunga - švedų - EMA (European Medicines Agency)

ceft biopharma s.r.o. - ibritumomabtiuxetan - lymfom, follikel - terapeutiska radioaktiva läkemedel - zevalin indikeras hos vuxna. [90y]-radioaktivt zevalin är indicerat som konsolidering terapi efter remission induktion i tidigare obehandlade patienter med follikulärt lymfom. förmån av zevalin följande rituximab i kombination med kemoterapi har inte fastställts. [90y]-radioaktivt zevalin är indicerat för behandling av vuxna patienter med rituximab relapsedorrefractory cd20+ follikulärt b-cells non-hodgkins lymfom (nhl).

Švedija - švedų - Läkemedelsverket (Medical Products Agency)

cipla europe nv - karboplatin - koncentrat till infusionsvätska, lösning - 10 mg/ml - karboplatin 10 mg aktiv substans

Europos Sąjunga - švedų - EMA (European Medicines Agency)

biosimilar collaborations ireland limited - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiska medel - abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. för vidare information om human epidermal growth factor receptor 2 (her2) status, se avsnitt 5. abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with abevmy in combination with capecitabine. för ytterligare information om her2-status, se avsnitt 5. abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics [figo] stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Švedija - švedų - Läkemedelsverket (Medical Products Agency)

medac gesellschaft für klinische spezialpräparate mbh - karboplatin - koncentrat till infusionsvätska, lösning - 10 mg/ml - karboplatin 10 mg aktiv substans

Švedija - švedų - Läkemedelsverket (Medical Products Agency)

navamedic asa - cefotaximnatrium - pulver till injektionsvätska, lösning - cefotaximnatrium 1,048 g aktiv substans - cefotaxim

Švedija - švedų - Läkemedelsverket (Medical Products Agency)

stragen nordic a/s - cefuroximnatrium - pulver till injektions-/infusionsvätska, lösning - 1,5 g - cefuroximnatrium 1,578 g aktiv substans - cefuroxim

Švedija - švedų - Läkemedelsverket (Medical Products Agency)

navamedic asa - cefuroximnatrium - pulver till injektions-/infusionsvätska, lösning - 1500 mg - cefuroximnatrium 1578 mg aktiv substans - cefuroxim

Švedija - švedų - Läkemedelsverket (Medical Products Agency)

stragen nordic a/s - cefuroximnatrium - pulver till injektionsvätska, lösning - 250 mg - cefuroximnatrium 263 mg aktiv substans - cefuroxim

Švedija - švedų - Läkemedelsverket (Medical Products Agency)

navamedic asa - cefuroximnatrium - pulver till injektions-/infusionsvätska, lösning - 250 mg - cefuroximnatrium 263 mg aktiv substans - cefuroxim

Švedija - švedų - Läkemedelsverket (Medical Products Agency)

navamedic asa - cefuroximnatrium - pulver till injektions-/infusionsvätska, lösning - 750 mg - cefuroximnatrium 789 mg aktiv substans - cefuroxim